Novo Nordisk's Victoza gets EU market green light
COPENHAGEN, July 3 (Reuters) - Danish pharmaceuticals group Novo Nordisk's (NOVOb.CO: Quote, Profile, Research) diabetes treatment Victoza has won European Commission approval for marketing across the EU, the company said on Friday.
"The European Commission has granted marketing authorisation for Victoza for the treatment of type 2 diabetes in adults," Novo Nordisk said in a statement, calling it an "important milestone."
The company will launch Victoza in the UK, Germany and Denmark this summer and in other European markets in the second half of 2009 and throughout 2010, it said.
"The marketing approval in Europe does not change Novo Nordisk's expectations for the company's financial results for 2009," it added.
© Thomson Reuters 2009 All rights reserved
Dubai Debt Fears
Banks outside the Gulf played down their exposure to Dubai debt, after fears the emirate could default and even derail world economic recovery prompted a sell-off in global markets. Full Article | Slideshow
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage
India
US
UK
